These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35203796)

  • 1. XDR-
    Del Giacomo P; Raffaelli F; Losito AR; Fiori B; Tumbarello M
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203796
    [No Abstract]   [Full Text] [Related]  

  • 2. Extensively drug-resistant
    Mendes Pedro D; Paulo SE; Santos CM; Fonseca AB; Melo Cristino J; Pereira ÁA; Caneiras C
    Front Microbiol; 2024; 15():1347521. PubMed ID: 38414772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
    Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
    J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
    Arca-Suárez J; Lasarte-Monterrubio C; Rodiño-Janeiro BK; Cabot G; Vázquez-Ucha JC; Rodríguez-Iglesias M; Galán-Sánchez F; Beceiro A; González-Bello C; Oliver A; Bou G
    J Antimicrob Chemother; 2021 Jan; 76(1):91-100. PubMed ID: 33083833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.
    Meschiari M; Franconi I; Bacca E; Bianco V; Orlando G; Cuomo G; Bedini A; Mussini C
    Infection; 2021 Jun; 49(3):549-553. PubMed ID: 33074365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.
    Pérez A; Gato E; Pérez-Llarena J; Fernández-Cuenca F; Gude MJ; Oviaño M; Pachón ME; Garnacho J; González V; Pascual Á; Cisneros JM; Bou G
    J Antimicrob Chemother; 2019 May; 74(5):1244-1252. PubMed ID: 30753505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
    Galani I; Papoutsaki V; Karantani I; Karaiskos I; Galani L; Adamou P; Deliolanis I; Kodonaki A; Papadogeorgaki E; Markopoulou M; Maraki S; Damala M; Prifti E; Vagiakou E; Petinaki E; Fountoulis K; Tsiplakou S; Kirikou H; Souli M; Antoniadou A; Giamarellou H
    J Antimicrob Chemother; 2020 Aug; 75(8):2164-2172. PubMed ID: 32449909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
    Shortridge D; Castanheira M; Pfaller MA; Flamm RK
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
    J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS; Castanheira M; Duncan LR; Mendes RE
    Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS; Huband MD; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6305-10. PubMed ID: 24100499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.
    Idowu T; Zhanel GG; Schweizer F
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
    Fernández-Esgueva M; López-Calleja AI; Mulet X; Fraile-Ribot PA; Cabot G; Huarte R; Rezusta A; Oliver A
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):474-478. PubMed ID: 32143893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.